KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Work In Process (2009 - 2015)

Gilead Sciences posted quarterly Work In Process of $542.0 million for Q4 2015, up 8.4% year-on-year from $500.0 million in Q4 2014, and up 8.4% on a QoQ basis from $500.0 million in Q4 2014.

Gilead Sciences (GILD) has 7 years of Work In Process data on file, last reported at $542.0 million in Q4 2015.

  • For the quarter ending Q4 2015, Work In Process rose 8.4% year-over-year to $542.0 million; the trailing twelve-month figure through Dec 2015 stood at $542.0 million (up 8.4% YoY), and the FY2015 full-year result was $542.0 million, up 8.4% from the prior year.
  • Work In Process for Q4 2015 stood at $542.0 million, up from $500.0 million in the prior quarter.
  • Across five years, Work In Process topped out at $563.9 million in Q2 2014 and bottomed at $175.5 million in Q3 2011.
  • The 5-year median for Work In Process is $412.9 million (2013), against an average of $398.7 million.
  • The widest annual swing landed in 2011, when Work In Process slumped 55.28%; it then gained 21.08% in 2014.
  • A 5-year view of Work In Process shows it stood at $466.5 million in 2011, then fell by 23.15% to $358.5 million in 2012, then grew by 15.18% to $412.9 million in 2013, then increased by 21.08% to $500.0 million in 2014, then increased by 8.4% to $542.0 million in 2015.
  • The last three Work In Process figures came in at $542.0 million (Q4 2015), $500.0 million (Q4 2014), and $563.9 million (Q2 2014), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2015 542.00 Mn
Dec 31, 2014 500.00 Mn
Jun 30, 2014 563.88 Mn
Dec 31, 2013 412.95 Mn
Dec 31, 2012 358.53 Mn
Dec 31, 2011 466.50 Mn
Sep 30, 2011 175.55 Mn
Jun 30, 2011 271.64 Mn
Mar 31, 2011 296.87 Mn
Dec 31, 2010 454.65 Mn
Sep 30, 2010 392.54 Mn
Dec 31, 2009 392.04 Mn